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Abstract   
 
Content: Identification of panel of SEREX-defined antigens for breast cancer autoantibodies profile detection. 
Objective: To create panel of antigens that can differentiate breast cancer patients and healthy individuals.  
Methods: SEREX (serological analysis of cDNA expression libraries) method, ELISA, qPCR.  
Results: In large-scale screening of 16 SEREX-antigens by sera of breast cancer patients and healthy donors a 
combination of 6 antigens (RAD50, PARD3, SPP1, SAP30BP, NY-BR-62 and NY-CO-58) was identified, 
which can differentiate breast cancer patients and healthy donors with 70% sensitivity and 91% specificity. 
Elevated mRNA expression of SPP1 gene was revealed in breast tumors (2-7 fold), that correlated with SPP1 
antigen immunoreactivity in autologous patients’ sera.  
Conclusions: The new panel of 6 SEREX-antigens was proposed which enables creation of serological assay 
for breast cancer diagnostics and/or prognosis.   
 
Key words: Tumor-associated antigens, breast cancer, autoantibody, antigenic panel. 
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Introduction 
Breast cancer is the most widespread cancer type in women. Many breast tumors with high histological 
tumor grade, mitotic index and proliferation rate are overrepresented among the so-called interval breast 
cancers (e.g. cancers arising between annual mammograms), that cannot be detected by currently existing 
methods, in particular mammography
 
(Collett et al., 2005). In a view of above mentioned facts an urgent need 
exists for creation and development of new alternative and/or complementary methods to improve breast cancer 
diagnostics and prognosis. In this sense, identification of serum biomarkers, that can be detected in patient’s 
blood by minimally invasive methods (i.e., peripheral blood sampling) is an urgent task.  
Over the last years emerging number of evidence suggests that each type of cancer might trigger unique 
autoantibody signatures, that reflect tumor-associated antigens (TAAs) repertoire and the nature of the 
malignant process in the affected organ. A large number of studies focused on assessment of serum anti-TAAs 
antibodies reported their as molecular biomarkers for a number of cancers including ovarian (Gnjatic et al., 
2010; Kim et al., 2010), breast (Piura et al., 2011; Anderson et. al., 2011), lung (Boyle et al., 2011), 
hepatocellular (Zhang et al., 2010), colorectal (Pedersen et al., 2011; Chan et al.., 2010), gastric carcinomas 
(Zayakin et al., 2013) etc. Their advantages over other biomarkers, including the TAAs themselves, are 
accessibility, persistence and high stability in the serum of cancer patients (Anderson et. al., 2005). 
Autoantibodies correspond to an efficient biological amplification of the presence of TAAs, and are secreted in 
the serum prior to first clinical signs. However, most serum autoantibodies, used as stand-alone diagnostic 
assays, demonstrate low sensitivity and/or specificity to be utilized as diagnostic tools (Desmetz et al., 2011). In 
this respect proposal has been made to combine several antigens into one panel for specific autoantibodies 
profiles (signatures) identification in patients with different cancer types, including breast cancer. To date 
several breast cancer antigenic panels for autoantibody detection (Piura et al., 2011; Lacombe et al., 2014) have 
been reported and most of them include well-known oncoproteins such as p53, p62, c-myc, MUC1, HER2, 
BRCA1, survin, cyclin D1 (Koziol et al., 2003; Zhang et al., 2003; Chapman et al., 2007; Lu et al., 2008; Ye et. 
al., 2013; Yahalom et al., 2013; Liu et al., 2015) etc. Sensitivity and specificity of currently existing breast 
cancer antigenic panels for serum autoantibodies profiles detection varies from 40% to 92% (Piura et al., 2011; 
Lacombe et. al., 2014). Recently, some autoantibody panels were created considering lymph node status 
(Lacombe et al., 2014),  age, race and current smoking status (Evans et al., 2014) of breast cancer patients and 
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some clinicopathological features of their tumors including tumor grade (Mange, 2012). No significant 
differences were seen when patients were subdivided by age, tumor size, histological grade or lymph node 
status in previous studies (Chapman et al., 2007). 
The aim of this study was to create optimal antigens combination among SEREX (serological analysis 
of cDNA expression libraries)-defined antigens which could distinguish breast cancer patients and healthy 
donors. For this purpose allogeneic screening of 16 SEREX- defined antigens has been performed using sera of 
cancer patients with different histological types and grades as well as status of ER, PR and HER2 receptors of 
their tumors. To evaluate the impact of TAAs expression level in patient tumor on the frequency of anti-TAAs 
antibodies in patient sera a paired autologous tumor and serum samples has been analyzed.  
During our previous studies focused on medullary breast carcinoma (MBC) investigation by SEREX-
approach 41 TAAs have been identified and characterized in preliminary phage-based allogenic screening
 
(Kiyamova et al., 2010; Kostianets et al., 2012). In the current study affinity purified recombinant analogues of 
13 the most immunogenic MBC antigens together with 3 previously defined by other researches SEREX-
antigens associated with breast cancer NY-BR-62, NY-BR-1 and NY-CO-58
 
(Jager et al., 2001; Scanlan et al., 
2001; Scanlan et al., 2002; Gnjatic et al., 2010) were tested in allogenic screening by ELISA with sera of 
healthy donors (n=35) and breast cancer patients (n=112) considering histological types and grades of their 
tumors, as well as status of  ER, PR and HER2 receptors. It was shown that 6 TAAs including RAD50, 
PARD3, SPP1, SAP30BP, NY-BR-62 and NY-CO-58 had higher immunogenicity in breast cancer patient’s 
sera compare with sera of healthy donors regardless their histological types and receptor status. Nevertheless, 
antibody response to PARD3 and SPP1 antigens was associated with more aggressive breast tumors. 
Subsequent ROC-analysis allowed to identify the optimal combination of 6 TAAs among 16 antigens tested 
which can differentiate cancer patients and healthy donors with high sensitivity (70%) and specificity (91%). 
Analysis of mRNA expression of the most immunogenic antigens SAP30BP, PARD3 and SPP1 in breast 
tumors by quantitative real-time PCR revealed elevated SPP1 gene expression in tumors compared with non-
cancerous tissue samples that was correlated with SPP1 antigen immunoreactivity in autologous patient’s sera. 
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Materials and Methods 
Patients serum and tissue samples 
Sera samples of breast cancer patients and healthy donors were collected during routine diagnostic procedures 
at the Dnipropetrovsk Clinical Oncological Center (Dnipropetrovsk, Ukraine) between 2008 and 2010 and 
stored with glycerol (50%) at – 20°C. In total, 112 patients with newly diagnosed breast cancer and 35 patients 
with no neoplasm (control group) were recruited to the study (Table 1). Among them 80 patients had invasive 
ductal carcinoma (IDC), 23 had invasive lobular carcinoma (ILC) and 8 had medullary breast carcinoma 
(MBC). Fresh cancer and non-cancerous breast tissue (NCT) samples were obtained from 17 female patients 
with primary breast carcinomas and 7 patients with fibrocystic disease correspondingly, which undergoing 
surgery in the Dnipropetrovsk Clinical Oncological Center (Dnipropetrovsk, Ukraine) between 2009 and 2011. 
Tissue samples were kept frozen in liquid nitrogen after resection. Breast cancer tissue samples (n=17) included 
invasive ductal carcinomas (n=10), invasive lobular carcinomas (n=2), and medullary breast carcinomas (n=5). 
In all patients with a clinical diagnosis of breast cancer, histology findings were reviewed to confirm the 
diagnosis. The diagnosis of cancer was verified on tissue samples by expert pathologist at the Dnipropetrovsk 
Clinical Oncological Center (Dnipropetrovsk, Ukraine). The study was approved by the Ethics Committee of 
the Institute of Molecular Biology and Genetics, NASU (Kyiv, Ukraine) and the Clinical Oncological Center 
(Dnipropetrovsk, Ukraine), and informed consent was obtained from all patients.  
Cloning, expression and purification of recombinant proteins 
cDNAs of 13 antigens including ANKRD11, RAD50, FAM50A, LGALS3BP, HMGN2, LRRFIP1, PABPC4, 
PARD3, PDCL, RBPJ, SAP30BP, SPP1, and TOP2B genes, isolated from MBC cDNA libraries, were cloned in 
bacteria using pGEX4T3, pET28b or pET42b expression vectors, containing glutation-S-transpherase (GST), 
6His and GST-6His sequences, respectively. Recombinant plasmids pET23d/NY-CO-58, pET23d/NY-BR-62, 
and pET24d/NY-BR-1 were kindly provided by Prof. Dirk Jager (National Center of Tumor Diseases, 
Heidelberg, Germany) and Dr. Mattew J. Scanlan (Ludwig Institute for Cancer Research, New-York, USA). 
Expression of fused recombinant proteins was induced by 1 mM IPTG at 37°C in LB-medium for 4h in E. coli 
BL21 (DE3) pLysE cells transformed by correspondent recombinant plasmids. Recombinant proteins were 
affine purified using GST-sepharose or Ni-NTA-agarose according to manufacturers’ protocols.  For 
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purification of RAD50, LRRFIP1, RBPJ, and SPP1 recombinant proteins, which were predominantly in 
inclusion bodies, the protocol designed by Yang et al.
 
(Yang et al., 2004) was used to increase their purity. 
Purity of antigens was defined by SDS-PAGE (Coomassie staining).   
 
 
ELISA 
To identify autoantibodies in patients’ sera samples ELISA (enzyme-linked immunosorbent assay) was 
performed using 96-well plates (Sarstedt, USA), which were coated by recombinant GST, GST-6His, 6His-
fused antigens (3 µg/ml) in PBS, pH 7.4 (3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl) 
overnight at +4°C. The plates were washed 4 times by PBS containing 0,1% Tween-20, blocked with 5% casein 
hydrolysate (USB, USA) in PBST 2h at 37°C and 100 µl of sera samples (diluted 1:100) with 0.5% casein 
hydrolysate in PBS were applied in duplicates for 90 min at 37°C. The plates were washed as described above 
and processed with 100 µl of anti-human Fc-specific IgG antibodies conjugated with horse radish peroxidase 
(Jackson Immuno Research, USA) diluted 1:10
4
 with 1% casein hydrolysate in PBS for 1h at 37°C. The plates 
were washed again and the signal was visualized with 100 µl of ABTS (2,2’azinodietiltiazolilsulfoate acid) 
substrate (Sigma, USA) for 30 min at 37C.  Optical density (OD) of wells was evaluated at A410 using 
spectrophotometer Multiscan (Labsystems, USA). 
 
Real-time quantitative RT-PCR  
Total RNA from 17 breast cancer and 7 non-cancerous breast tissue samples was isolated by the guanidinium 
thiocyanate method
 
(Chomczynski et al., 1987).  3 µg of RNA was converted into cDNA using M-MuLV 
Reverse Transcriptase (Fermentas, USA) at 37°C for 60 min using oligo (dT)18 primers in 20 µl reaction 
volume according to the standard protocol of manufacturer (Fermentas, USA). Gene-specific PCR primers were 
designed using NCBI software Primer-BLAST (URL:http://www.ncbi.nlm.nih.gov/tools/primer-blast/). qPCR 
reactions were prepared in duplicates using 50 ng of cDNA diluted in SYBR Green I Master Mix ×2 buffer 
(Fermentas, USA) with 9 pmol of corresponding gene-specific forward and reverse primers. The following 
thermal conditions were applied: 95°C for initial denaturation (30s) and 40 cycles consisting of 95°C 
denaturation (10s), 55°C annealing (5s), and 60°C extension (60s). Thermal cycling and fluorescent monitoring 
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were performed using iCycler iQ5 PCR thermal cycler (Bio-Rad, CA, USA). Cycle threshold (Ct) was 
determined and normalized against Ct value of the actin (ACTB) endogenous control product (∆Ct= Ct target 
gene — Ct ACTB). For 7 non-cancerous breast cDNA samples normalized ∆Ct was calculated as the mean 
value. The relative concentrations of gene-specific mRNAs in breast cancer tissues compared to non-cancerous 
breast tissues were calculated by subtracting the normalized mean ∆Ct value obtained for non-cancer breast 
tissues from those obtained for each of 17 tumor samples (∆Ct = ∆Ct of tumor—mean ∆Ct for 4 non-cancer 
breast). The relative concentration was determined as 2 
∆∆Ct
 (Kubista et al., 2006). 
Statistical analysis 
Primary data systematization and analysis was performed using Exсel software (Microsoft Office, 2007). 
Serum samples were considered as positive for the presence of autoantibodies when their optical density (OD) 
according to ELISA data exceeded the accepted cut-off for an assay to the antigens. The cut-off of the test was 
considered as the mean plus 3 standard deviations of the OD values of all healthy donors’ samples. To 
determine whether the frequency of autoantibodies to each of 16 TAAs was significantly higher in sera of 
breast cancer patients compare with sera of healthy donors, data were analyzed using the Fisher two-sided exact 
test. A p value 0.05 was considered as a statistically significant. SPSS 17.0 (USA) and Graphpad Prism 5.0 
(USA) were used to compute sensitivity and specificity, and to generate receiver operator characteristic (ROC) 
curves. Area under the curve (AUC) for each autoantibody also was tested to determine differences from 
chance. Spearman rank tests were used for pairwise correlations among immunogenicity and mRNA expression 
levels of antigens. 
 
Results 
Antigens for serological analysis by ELISA 
16 potential tumor-associated antigens, previously identified by SEREX analysis of breast and colon cancer 
cDNA libraries
 
(Kiyamova et al., 2010; Kostianets et al., 2012; Jager et al., 2001; Scanlan et al., 2001; Scanlan 
et al., 2002) were selected for current study. Twelve out of 13 antigens (RAD50, FAM50A, LGal3SBP, 
HMGN2, PARD3, SAP30BP, ANKRD11, SPP1, PDCL, PABCP4, RBPJ, LRRFIP1) identified in MBC cDNA 
library  had tumor-associated serological profile of autoantibodies according to the data of phage based 
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allogeneic screening of all 41 identified medullary breast carcinoma autoantigens (Kostianets et al., 2012). 
TOP2B MBC antigen was included in this study as potential tumor antigen and target for cancer treatment 
(Cowell et al., 2000; Wang, 1996),
 
although it had not demonstrated high level of immunoreactivity in cancer 
patient’s sera according our data (Kostianets et al., 2012). In addition, 3 breast cancer associated antigens 
identified during serological screening of cDNA libraries from breast  (NY-BR-1
 
(Jager et al., 2001), NY-BR-
62 (Scanlan et al., 2001) and colorectal (NY-CO-58 )
 
(Scanlan et al., 2002; Gnjatic et al., 2010) tumors were 
kindly provided for analysis by Prof. D. Jager and Dr. М. Scanlan were  included in  this screening. 
cDNAs of all selected antigens were cloned in frame with GST-, GST-6His-, and His-tags in 
correspondent vectors and expressed in bacteria (Table 2). Purified recombinant TAAs (full-size proteins or 
their immunogenic fragments) were used as antigens in ELISA screening (Table 2) of breast cancer patients 
(IDC, ILC, MBC) and healthy donors sera.   
Evaluation of the frequency of antibody response in sera of breast cancer patients toward TAAs 
A frequency of autoantibodies in breast cancer patients sera directed against each individual recombinant 
antigen was evaluated by ELISA. Sera of 112 patients with breast tumors of different histological types and 
grades, and sera of 35 healthy donors, which were obtained from the same geographical region, were included 
in the analysis. The data of allogenic screening presented in Table 3 demonstrate that the autoantibody 
frequency in sera of breast cancer patients to individual TAAs varied from 0 to 21.7%.  Frequency of 
autoantibodies in cancer patient sera was significantly higher compare to healthy individuals only for 6 out of 
16 antigens (RAD50, NY-CO-58, PARD3, SAP30BP, SPP1 and NY-BR-62) and increased frequency of 
antibody response to NY-BR-62 antigen was found only in sera of ILC patients, but not in sera of cancer group 
patients (Table 3). As for individual antigens, the frequency of autoantibodies varied in patients with different 
histological types of breast tumors. In patients with IDC the highest immune reactivity was detected for RAD50 
(18,8%), SPP1 (18.8%), NY-CO-58 (16.3%), PARD3 (15%), and SAP30BP (15%) antigens, while in patients 
with MBC - for SAP30BP (22.2%) and SPP1 (33.3%) antigens, and in patients with ILC - for NY-BR-62 
(26.1%), PARD3 (21.7%) and SAP30BP (13%) antigens. However we did not find statistically significant 
differences of antibody response between groups of cancer patients with tumors of different histological 
types.     
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So, statistically significant difference was found between autoantibodies existence to 6 antigens in sera of 
cancer patients predominantly with IDC histological type compare with frequency of autoantibody response in 
sera of healthy donors, but not between groups of patients with different histological types. 
Frequency of antibodies to RAD50, NY-BR-62, NY-CO-58, PARD3, SAP30BP, and SPP1 was further 
assessed considering tumors grade (Table 4). Histological tumor grade is based on the degree of differentiation 
of the tumor tissue and is determined according to Nottingham histologic score. In breast cancer, it refers to the 
semi-quantitative evaluation of morphological characteristics of tumor tissue sections. This grading method 
evaluates three parameters and assigns a score of 1 to 3 for each parameter as follows: tubule formation (> 75%, 
1; 10–75%, 2; < 10%, 3), nuclear pleomorphism (none, 1; moderate, 2; pronounced, 3), and number of 
mitoses/10 high power fields (HPF), based on a HPF size of 0.274 mm2 (< 10 mitoses, 1; 10–19 mitoses, 2; ≥ 
20 mitoses, 3). The final grade is based on the sum of the scores of the three parameters: 3, 4, or 5 = grade 1; 6 
or 7 = grade 2; and 8 or 9 = grade 3) (Elston et al., 1991; Frkovic-Grazio et al., 2002).  
Autoantibodies to NY-CО-58 and SAP30BP were detected only in patients with G2 and G3 tumors, to 
RAD50, SPP1, and NY-BR-62  in all breast cancer patients irrespectively of tumor grade, and to PARD3 – only 
in patients with G3 tumors. It should be noted that statistically significant difference between frequencies of 
autoantibodies in the groups of patients with tumors of different grade was shown only for SPP1 antigen in the 
groups of patients with G1 and G3 tumors (Table 4).  
 No correlation between autoantibodies existence to all 16 antigens with molecular (HER2-, ER-, PR-
status) variables of tumors of cancer patients was found during this study (data not shown). 
Assessment of potential immunodiagnostic value of antigens combination 
To assess immunodiagnostic value for each of 16 antigens we detected their predictive accuracies by logistic 
regression model (ROC-analysis). Predictive accuracies of selected antigens was evaluated in accordance with 
sensitivity and specificity values as well as AUC scale which can be classified as middle (AUC>0,6) and good 
(AUC>0,7). Table 5 presents sensitivity and specificity and AUC values of the most immunogenic 6 antigens 
according to ROC-analysis of allogenic screening data. According to these data all of the TAAs demonstrated 
quite low sensitivity values when analyzed separately.  
Further we analyzed different combinations of all 16 antigens and found optimal antigenic combination, 
that included all 6 antigens with highest  immunoreactivity in breast cancer patient’s sera and which could 
distinguish cancer patients and healthy donors with 70% sensitivity, and specificity to 91%, AUC=0,808 [95% 
CI, 0.736-0.879] (Figure 1). 
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Evaluation of SPP1, PARD3, and SAP30BP mRNAs expression in breast carcinomas of different 
histological type by quantitative real time PCR  
Taking into account that autoantibody production in human body may be caused by overexpression of the 
correspondent proteins in breast tumors, we examined the expression profile of some antigens such as SPP1, 
PARD3, SAP30BP in 17 breast carcinomas of various histological types (IDC, ILC, MBC) and 7 non-
cancerous tissue samples by real-time PCR. These antigens were selected for analysis because of their highest 
sensitivity compare with other studied antigens according to ROC-analysis data (see above). The results of 
relative gene expression analysis of 3 genes in breast tumors are shown in Figure 2. Notably that mRNA 
expression of SPP1 was 2-7 fold upregulated compared with noncancerous tissue samples in 11 out of 17 breast 
tumor samples (Figure 2). At the same time PARD3 and SAP30BP mRNA levels in the most tumor samples did 
not differ from the respective mRNAs levels in non-cancerous tissue samples. The difference between 
expression values in cancer and normal tissues was statistically significant only in case of SPP1 antigen 
(13.7±12.55 vs. 2.14±1.57, two-tailed U-test p=0.0051).  
Taking into account this finding it was interesting to study whether gene expression of TAAs correlated 
with immunoreactivity of respective antigen in the sera of the same patient. For this purpose paired autologous 
tumor tissue and sera samples obtained from 17 breast cancer patients were analyzed in respect of SPP1, 
PARD3 and SAP30BP genes expression in tumors and immunoreactivity of correspondent antigen in sera. The 
moderate positive correlation (r = 0.393028) between TAA gene expression and its immunoreactivity in 
autologous sera was detected only for SPP1 (see Figure 3). 
 
Discussion 
The identification and study of TAAs and corresponding autoantibodies for cancer diagnostics, 
monitoring and therapy became the key trend stream of investigations focused on malignant tumors biomarkers 
research in the last 20 years. The aim of the current study was to characterize SEREX-defined antigens and 
determine autoantibodies profiles, which could differentiate patients with breast cancer and healthy donors. For 
this purpose large-scale allogenic screening of previously identified 16 SEREX-antigens was performed by 
ELISA followed by ROC-analysis of results obtained. The frequency of autoantibodies directed against above 
mentioned antigens in sera of 112 patients with different clinicophatological characteristics of breast 
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carcinomas compared with sera of 35 healthy donors was assessed. Autoantibody frequency for individual TAA 
varied in groups of patients with tumors of different histological types. In IDC patients the most abundant were 
autoantibodies to RAD50, NY-CO-58, NY-ВR-62, PARD3, SAP30BP, SPP1; in MBC patients – to SAP30BP 
and SPP1; while in the group of ILC patients to PARD3, SAP30BP, and to NY-ВR-62. So, 6 antigens (RAD50, 
NY-CO-58, PARD3, SAP30BP, SPP1 and NY-BR-62) of 16 showed individual significant difference between 
breast cancer patients and healthy donors demonstrating ability to discriminate these cohorts. 
Notably, no significant difference in frequency of autoantibodies between the groups of patients with 
tumors of different histological types and ER, PR, HER2 status was detected in case of any antigen tested. 
However, when tumor grade was taken into account antibody to the PARD3 antigen was detected exclusively 
in sera of patients with more aggressive disease, suggesting that PARD3 as a potential prognostic marker. In 
addition, significant decrease of autoantibody frequency with increasing of tumors grade was detected for SPP1 
antigen. It may be explained in part by existence of anti-SPP1 autoantibody and SPP1 protein immune 
complexes at the advanced stages of breast tumor development especially that elevated serum level of SPP1 
protein has been previously shown in sera of patients with more aggressive breast tumors
 
(Fedarko et al., 2001). 
The existence of immune complexes in breast cancer patients’ sera has been already described for glycolysis 
and splicesome proteins
 
(Ladd et al., 2013). Authors indicated that immune complex formation with increasing 
levels of antigen is one possible explanation for the observed decrease of autoantibody signal closer to 
diagnosis and suggest, that formation of these complexes may explain the observed immune suppression in 
breast cancer patients
 
(Ladd et al., 2013).  
Among these 6 antigens we are the first who described increased frequency of antibody response toward 
SPP1, RAD50, PARD3 and SAP30BP antigens in sera of breast cancer patients compared with sera of healthy 
women. This fact may indicate these antigens as potential molecular markers of breast tumors.  In this 
connection, association with breast cancer was already described for SPP1 (Wai et al., 2004; Rodrigues et al., 
200;, Tilli et al., 2011) and RAD50
 
(Tomminska et al., 2006; Bartkova et al., 2008) antigens.  
SPP1 (osteopontin) is a secretory protein, which mediates cell adhesion, chemotaxis, contributes to 
apoptosis avoidance, and is associated with many cancer types
 
(Wai et al., 2004) including breast cancer 
(Rodrigues et al., 2007; Tuck et al., 2007). It should be noted that elevated level of serum autoantibodies to 
SPP1 was shown only in patients with prostate cancer
 
(Tilli et al., 2011). RAD50 is a highly conserved DNA 
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double-strand break repair factor
 
(Dolganov et al., 1996). The mutations which lead to RAD50 gene 
inactivation, increase predisposition to pancreas and breast cancers development
 
(Wang et al., 2008). PARD3 
(Рar-3 partitioning defective 3 homolog C. elegans) is an adapter protein involved in asymmetrical cell division 
and cell polarization processes. It was shown that this protein is down regulated in primary esophageal 
squamous cell carcinoma compare to normal tissues
 
(Zen et al., 2009). Cell functions and expression pattern of 
SAP30BP (SAP30-binding protein) are still unknown. 
Immunoreactivity of the rest two antigens, namely NY-CO-58
 
(Gnjatic et al., 2010) and NY- and BR-62 
(Scanlan et al., 2001), already has been studied in cohorts of patients with different cancer types.  NY-CO-58 
plays a central role in chromosome segregation during mitosis, proliferation and possibly in tumor growth
 
(Gnjatic et al., 2010). Sequence of gene encoding NY-CO-58 is similar to kinesin family member 2C (KIF2C), 
which upregulated expression was detected by a genome-wide microarray analysis of breast cancer tissues
 
(Shimo et al., 2008). Of note, antigen NY-BR-62 also is similar to kinesin 2 and can be involved in 
chromosome segregation during mitosis
 
(Sueishi et al., 2000). Data of immunoreactivity of NY-BR-62 and NY-
CO-58 antigens in sera of breast cancer patients received during this study are consistent with those of other 
authors
 
(Scanlan et al., 2001; Scanlan et al., 2002).  
So, large-scale allogenic screening allowed us to characterize immunoreactivity of 16 SEREX-defined 
antigens in sera of breast cancer patients and select 6 the most immunogenic antigens including RAD50, 
PARD3, SPP1, SAP30BP, NY-BR-62 and NY-CO-58. ROC-analysis of antibody response toward all 16 
antigens led to identification of the optimal combination that included 6 antigens with the highest 
immunoreactivity in breast cancer patients’ sera.  This panel of 6 antigens can differentiate breast cancer 
patients and healthy donors with high sensitivity and specificity (70% and 91% correspondently). Since these 
antigens and autoantibodies thereto are potential breast cancer biomarkers, they could be used for creation of 
new and/or improving sensitivity and specificity of already existing antigenic/autoantibody signatures for breast 
cancer detection. For today several antigenic panels were already proposed for autoantibodies profile 
identification in breast cancer patients by different researchers with a wide range of sensitivity, specificity and 
AUC. As it was mentioned above the most of breast cancer antigens panels include widely characterized and 
well-known antigens, which were identified by different approaches predominantly without preliminary study 
of immunoreactivity in sera of cancer patients. Notable that breast cancer antigenic panels which were created 
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on the base of preliminary serological analysis (SEREX, SEPRA or other techniques) possess higher sensitivity 
compared with other antigenic panels
 
(Zhong et al., 2008; Piura et al., 2010; Lacombe et al., 2013; Dong et al., 
2013). Summarizing this fact together with our data we suggest that application of serological approaches for 
TAAs identification and characterization leads to the creation of the most sensitive combinations of new 
antigens important for further development of minimally invasive breast cancer detection assays.   
To understand a possible mechanism underling the increased immunoreactivity of autologous proteins 
we examined the gene expression for 3 of the most immunogenic antigens including SPP1, PARD3 and 
SAP30BP in breast tumors and noncancerous tissue samples. The elevated mRNA expression level in breast 
tumors was found only for SPP1 antigen which correlates with its increased immunoreactivity in autologous 
patients’ sera samples. One may be supposed that the reason of autoantibody response toward SPP1 in breast 
cancer patients may be caused by its elevated level in sera of breast cancer patients (Liang et al., 2011; Fedarko 
et al., 2001), which in turn may be caused by increased SPP1 gene expression in breast tumors showed during 
this study. Moreover, taking into account literature data about elevated expression of osteopontin in tumors of 
high grade
 
(Chakraborty et al., 2008) and our data showing decreased level of autoantibody to SPP1antigen in 
correspondent patients’ sera detected by ELISA, we supposed that immune complexes may be formed at 
advanced stage of breast cancer disease. 
 
Conclusions 
The new combination of 6 antigens including RAD50, NY-CO-58, PARD3, SAP30BP, SPP1 and NY-
BR-62 for autoantibodies profile detection, which can distinguish breast cancer patients and healthy individuals 
with 70% sensitivity and 91% specificity regardless histological types and receptor status of their tumors, was 
proposed. Antibody response toward PARD3 and SPP1 antigens may be associated with more aggressive breast 
tumors. Analysis of MBC TAAs and other SEREX-antigens performed in this study provides information that 
can be used not only for application of potential breast cancer biomarkers, but also for understanding of 
molecular events involved in breast cancer initiation and progression.  
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 Figure 1. The ROC curve obtained from the analysis of six top TAAs (RAD50, NY-BR-62, NY-CO-58, 
PARD3, SAP30BP, SPP1). The false positive rate (1-specificity (x-axis)) is plotted against the true positive rate 
(sensitivity (y-axis)) for each cut-off point applied. AUC = 0.945, 95% confidence interval = 0.895 − 0.996). 
AUC=0,808 [95% CI, 0.736-0.879]. 
 
 
 
Figure 2. Analysis of SPP1, PARD3, SAP30BP mRNAs expression levels in breast cancer (BC) (n=17) and 
noncancerous tissues (NT) samples (n=9). The value of mRNA levels is expressed in arbitrary units of 
normalized actin expression level. 
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 Figure 3. Analysis of SPP1 gene expression and immunoreactivity of SPP1 antigen in the sera of the 17 breast 
cancer patients. 
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Table 1. Molecular and clinicopathological characteristics. 
Characteristics Serum samples Tissue samples 
Control group   
Number of patients 35 7 
Age at diagnosis, years (range) 17-60 28-49 
Mean ± SD (years) 39.2±12.56 40.2±10.04 
Group of cancer patients   
Number of patients 112 17 
Age at diagnosis, years (range) 19-82 35-82 
Mean ± SD (years) 59.49±17.2 59.22±12.7 
Tumor type   
          invasive ductal breast carcinoma 80 10 
          invasive lobular breast carcinoma 23 2 
          medullary breast cancer 9 5 
Tumor grade (%* from general) 82 86 
 grade 1 – 7.3 grade 1 – 0 
 grade 2 – 33.9 grade 2 – 22.2 
 grade 3 – 59.8 grade 3 – 77.8 
ER-status (%*) 52 76 
                       Positive 71.1 78.1 
                       Negative 28.9 21.9 
PR-status (%*) 52 76 
                       Positive 30.8 62.5 
                       Negative 69.2 37.5 
HER-2/neu status (%*) 52 76 
                       Positive 30.8 31.3 
                       Negative 69.2 68.7 
Lymphoid nodes status (% of positive) 28.8 20  
* Tumor grade, ER-, PR-, HER-2/neu status was known not for all tissue samples, the respective % of tumors with known 
characteristics is indicated in the table.  
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Table 2. Antigens selected for serological screening 
Antigen Full name NCBI reference 
(sequence number) 
cDNA fragment, 
bp 
Vector 
ANKRD11 Homo sapiens ankyrin repeat domain 11 NM_013275.4 951-1811 pGEX4T3 (GST-tag) 
RAD50 Homo sapiens RAD50 homolog 
(S. cerevisiae) 
NM_005732.2 2552-3374 pET28b (6His-tag) 
FAM50A Homo sapiens family with sequence 
similarity 50, member A 
NM_004699.1 76-1095 pGEX4T3 (GST-tag) 
LGALS3BP Homo sapiens lectin, galactoside-binding, 
soluble, 3 binding protein 
NM_005567.2 1483-1686 pGEX4T3 (GST-tag) 
HMGN2 Homo sapiens high-mobility group 
nucleosomal binding domain 2 
NM_005517.3 191-463 pGEX4T3 (GST-tag) 
LRRFIP1 Homo sapiens leucine rich repeat (in FLII) 
interacting protein 1 
NM_004735.2 417-1804 pET28b (6His-tag) 
PABCP4 Homo sapiens poly(A) binding protein, 
cytoplasmic 4 (inducible form) 
NM_003819.2 927-3052 pET28b (6His-tag) 
PARD3 Homo sapiens par-3 partitioning defective 3 
homolog (C. elegans) 
NM_019619.2 714-1416 pGEX4T3 (GST-tag) 
PDCL Phosducin-like protein NM_005388.3 97-1002 pET28b (6His-tag) 
RBPJ Homo sapiens recombination signal binding 
protein for immunoglobulin kappa J region 
NM_203284.1 492-1850 pET28b (6His-tag) 
SAP30BP SAP30 binding protein NM_013260.6 67-981 pGEX4T3 (GST-tag) 
SPP1 Homo sapiens secreted phosphor-protein 1 
(osteopontin) 
NM_000582.2 166-1068 pET42b (GST-6His-tag) 
TOP2B Homo sapiens topoisomerase (DNA) II beta 
180 kDa 
NM_001068.2 2383-4866 pGEX4T3 (GST-tag) 
NY-BR-1 ankyrin repeat domain-containing protein 
30A 
NM_052997.2 - pET24d (6His-tag) 
NY-BR-62 Kinesin-like protein KIF15 NM_020242.2 1-451 pET23d (6His-tag) 
NY-CO-58 Kinesin family member 2C NM_006845.3 194-648 pET23d (6His-tag) 
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Тable 3. Frequency of autoantibody detection to 16 tumor-associated antigens in patients with different types of 
breast carcinomas  
Antigens 
HD
a
 
(n=35) 
C
a
 
(n =112) 
MBC
a 
(n=9) 
IDC
a
 
(n=80) 
ILC
a
 
(n=23) 
Number of positive sera
b
 n(%) 
ANKRD11 1 (2,9) 3 (2,7) 0 2 (2,5) 1 (4,3) 
RAD50 0 18 (16,1)
** 1 (11,1)
 
15 (18,8)
** 
2 (8,7) 
FAM50A 1 (2,9)
 
4 (3,6)
 0
 
4 (5) 0 
LGAL3BP 0
 
8 (7,1) 0 6 (7,5) 2 (8,7) 
HMGN2 1 (2,9) 7 (6,3) 0 5 (6,3) 2 (8,7) 
LRRFIP1 1 (2,9) 1 (0,9) 0 1 (1,3) 0 
NY-BR-1 0 5 (4,5) 0 4 (5)
 
1 (4,3) 
NY-BR-62 1 (2,9) 14 (12,5)
 
0 8 (10)
 
6 (26,1)
* 
NY-CO-58 1 (2,9) 17 (15,2)
* 
2 (22,2)
 
13 (16,3)
** 
2 (8,7)
 
PABCP4 1 (2,9) 4 (3,6) 0 3 (3,8) 1 (4,3) 
PARD3 1 (2,9)
 
17 (15,2)
**   0
 
12 (15)
** 
5 (21,7)
* 
PDCL 2 (5,7) 7 (6,3) 1 (11,1) 6 (7,5) 0 
RBPJ 0 8 (7,1)
 
0 5 (6,3)
 
3 (13) 
SAP30BP 0
 
17 (15,2)
** 
2 (22,2)
* 
12 (15)
** 
3 (13)
* 
SPP1 1 (2,9) 19 (17,1)
* 
3 (33,3)
* 
15 (18,8)
** 
1 (4,3)
 
TOP2B 0 2 (1,8)
 
0 2 (2,5)
 
0
 
 
a
HD – healthy donors; C – all histological types of breast carcinoma, MBC – medullary breast carcinoma, IDC 
– invasive ductal carcinoma, ILC – invasive lobular carcinoma. * р<0,05, **р<0,01, ***р<0,001.  
b 
Cut-off: mean of healthy donors group plus 3 SD;  
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Table 4. Frequency of autoantibodies in sera of patients with tumors of different grades 
c 
                    
Grade  RAD50 NY-BR-62 NY-CO-58 PARD3 SAP30BP SPP1 
 
G1,n=6 
 
33,3(2)
 
 
22,2(2) 
 
 
0 
 
0 
 
0 
 
50(3)
   
G2, n=27 14,8(4)
 
7,4(2) 18,5(5) 0 11,1(3) 14,8(4)   
G3, n=49 12,2(6)
 
14,3(7) 14,3(7) 14,3(7)
 **
 14,3(7)
 
14,3(7)
*
   
c 
% of positive sera (n) 
*
 compare with G1  group,
 р<0,05  
**
 compare with G2 group,
 р<0,05  
 
 
 
 
 
Table 5. Sensitivity and specificity of 6 top individual TAAs detected by ROC-analysis 
Antigen AUC
 
Р-value Sensitivity (%) Specificity (%) 
RAD50 0,624 0,02666 9,29 100 
NY-BR-62 0,647 0,00871 13,39 97,14 
NY-CO-58 0,709 0,00019 12,50 97,14 
PARD3 0,689 0,00076 32,14 88,57 
SAP30BP 0,647 0,00871 33,04 91,43 
SPP1 0,744 <0,0001 41,07 85,71 
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